Nurtec™ ODT (rimegepant) orally disintegrating tablets 75 mg

Tips to Appeal a Coverage Denial for Nurtec™ ODT (rimegepant)

If your patient's health plan denies coverage for Nurtec ODT, you may be able to overturn this decision through the health plan's appeal process. A Letter of Appeal allows you to further explain your rationale and clinical decision making for prescribing Nurtec ODT and request that the health plan approve coverage. The information below can help guide you and your office staff through the process of drafting and submitting a Letter of Appeal. Be sure to check with your patient's health plan to confirm the specific process, as there may be varying levels of appeals. The process for most plans is generally time sensitive and initiates at the time of the denial.

Letter of Appeal Best Practices

- If not stated in the denial communication, confirm with the health plan if the letter should be addressed to a specific person or department
- Identify additional documents to help support your rationale for treatment with Nurtec ODT, which may include:
  - Relevant patient medical records
  - Nurtec ODT Prescribing Information
  - Nurtec ODT FDA approval letter (this can be found on the FDA website)
  - Peer-reviewed literature, including published clinical trial data for Nurtec ODT
- Draft the letter on your practice's letterhead
- Be sure to include the following information about your patient at the beginning of the letter:
  - Name
  - Date of birth
  - Case ID number (if known)
  - Health plan policy and group numbers
  - Date of service
- State that you are writing on behalf of your patient to appeal the denial of coverage for Nurtec ODT (rimegepant)
- Use exact language from the health plan's denial letter when explaining the reasons for denial
- Explain why Nurtec ODT is an appropriate treatment for your patient
  - If appropriate, include clinical trial results from peer-reviewed literature or the Nurtec ODT Prescribing Information to support the clinical rationale
- State why the preferred agents would not be appropriate therapies for your patient
- Describe your patient's condition with appropriate ICD-10-CM codes (eg, G43: Migraine, G43.0: Migraine without aura, G43.1: Migraine with aura, G43.9: Migraine, unspecified),[1] including existing comorbidities and allergies

To request information on Nurtec ODT, submit a Medical Inquiry Request Form by contacting Biohaven at 1-833-4NURTEC (1-833-468-7832) or visiting www.Nurtec-HCP.com.

INDICATION

Nurtec ODT (rimegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use

Nurtec ODT is not indicated for the preventive treatment of migraine.

Please see next page for Important Safety Information and click here for full Prescribing Information.

Nurtec™ ODT (rimegepant) orally disintegrating tablets 75 mg

Letter of Appeal Best Practices (cont.)

- List your patient's current and previous therapies, including:
  - Dosage
  - Frequency
  - Dates of use
  - Reason(s) for discontinuation (eg, therapeutic failure, contraindications, intolerance/adverse events)
- Provide your contact information (eg, phone number, email address, fax number) in case the health plan needs more information to reassess coverage
- List any additional documents included with the letter
- Submit the letter and documentation using the method preferred by the health plan (eg, fax, online portal)

Visit www.Nurtec-HCP.com/savings-support to download a Letter of Appeal template for Nurtec ODT.

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: *Pregnant/breast feeding*: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. *Hepatic impairment*: Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment*: Avoid use in patients with end-stage renal disease.

Please click here for full Prescribing Information.

Reference: 1. Center for Diseases Control and Prevention. ICD-10-CM tabular list of diseases and injuries. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2020. Updated June 19, 2019. Accessed September 25, 2020.

biohaven™ pharmaceuticals